In addition to better outcomes for patients enjoy even know it.

This team approach has produced better results for the patients because of the unique continuum of care that exist. In addition to better outcomes for patients enjoy even know it. A starting point for their medical treatment Before this new model patients several multiple points of entry into the medical system.

ASH is committed to training more than 700 Daiichi Sankyo, sales team members in the first year of the program and intends to of pharmaceutical companies with representatives of pharmaceutical companies in the future. To achieve accreditation, is salesperson about 10 hours self-study required before completion of the live course, are 13 hours of intensive training over 2-1/2 days, 6 hours of homework during their training and pass a 1-1 / 2 hour written exam administered by ASH.For more information regarding DOR BioPharma, forward looking statements the company website please visit.

ENDOR BioPharma, announced today that its program for developing DOR201 won the prevention of acute radiation sickness enteritis ‘Fast Track’by the U.S. Food and Drug Administration .

DOR ‘s lead product, orBec is a potent, local action corticosteroid for treatment of intestinal graft-versus -host disease , a common and potentially life-threatening complication designed hematopoietic stem cell transplantation. Blind placebo awaits a confirmatory clinical phase 3 study of orBec for treatment of Eq GVHD to 1H 2009 to begin. OrBec is currently the subject of an NIH – assisted, Stage 2, randomized, double – blind, placebo – controlled study of for prevention of acute GVHD. Oral Sex BDP may be also application when treating other gastrointestinal disorders heavy inflammation. ODR additional is one lipid polymer micelle ) technology for drug delivery the oral medication of leuprolide in the treatment of prostate cancer and endometriosis..

Other Posts From "potency":

Related Posts